Immune restoration disease in HIV patients: aberrant immune responses after antiretroviral therapy
- PMID: 12553688
Immune restoration disease in HIV patients: aberrant immune responses after antiretroviral therapy
Abstract
Suppression of HIV replication by antiretroviral therapy has various effects on the immune system of HIV-infected patients. Whereas protective pathogen-specific immune responses are restored in some patients, others have persistent immunodeficiency or produce immunopathological responses against opportunistic pathogens that cause immune restoration disease (IRD). Significant morbidity and even mortality may result from IRDs associated with infections by mycobacteria, herpesviruses, hepatitis viruses or the JC virus. Preliminary evidence from our studies suggests that immune responses in patients with IRD may be dysregulated and affected by immunogenetic factors. Thus, herpesvirus IRDs were associated with increased plasma levels of bioavailable interleukin-6 and soluble CD30, while mycobacterial and herpesvirus IRDs were associated with a major histocompatibility complex gene haplotype and/or alleles of particular cytokine genes. A greater understanding of pathogenic mechanisms and the immunogenetics of IRDs may lead to improved preventive and management strategies.
Similar articles
-
Antiretroviral therapy. Immune restoration disease in HIV-infected patients on HAART.AIDS Read. 1999 Nov;9(8):548-9, 554-5, 559-62. AIDS Read. 1999. PMID: 11082733 Review.
-
Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy.J Infect Dis. 2001 Oct 15;184(8):1073-7. doi: 10.1086/323599. Epub 2001 Sep 13. J Infect Dis. 2001. PMID: 11574925
-
Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution.Clin Infect Dis. 2002 Nov 15;35(10):1250-7. doi: 10.1086/344056. Epub 2002 Oct 28. Clin Infect Dis. 2002. PMID: 12410486
-
Immune restoration disease in HIV-infected individuals receiving highly active antiretroviral therapy: clinical and immunological characteristics.Neth J Med. 2003 Dec;61(12):408-12. Neth J Med. 2003. PMID: 15025416
-
Molecular biological assessment methods and understanding the course of the HIV infection.APMIS Suppl. 2003;(114):1-37. APMIS Suppl. 2003. PMID: 14626050 Review.
Cited by
-
Long-term safety from the raltegravir clinical development program.Curr HIV Res. 2011 Jan;9(1):40-53. doi: 10.2174/157016211794582650. Curr HIV Res. 2011. PMID: 21198432 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical